Thrombolytic therapy represents a new medical approach to the treatment of patients with thrombo- embolic disease. 1 Streptokinase and urokinase are presently the only two thrombolytic drugs in use. The advantage of thrombolytic agents is that they can dissolve thromboemboli, unlike the more con- ventional anticoagulant therapy with heparin and coumarin which is capable only of prevention of future clots. 2 Thrombolytic drugs, therefore, are able to permit the return of blood flow through the